Post-translational modifications in the context of therapeutic proteins

Nature Biotechnology

Volumn 24, Issue 10, 2006, Pages 1241-1252

  Walsh, Gary ^a   Jefferis, Roy ^b  

^a UNIVERSITY OF LIMERICK   (Ireland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATION; POST-TRANSLATIONAL MODIFICATION (PTM); STRUCTURAL-FUNCTIONAL RELATIONSHIPS;

ALKYLATION; DRUG PRODUCTS; MOLECULAR STRUCTURE; OPTIMIZATION;

PROTEINS;

ANTIBODY; GLYCOPROTEIN; GONADOTROPIN; INTERFERON; OLIGOSACCHARIDE; PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

AMIDATION; CARBOXYLATION; HYDROXYLATION; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SULFATION;

GLYCOPROTEINS; GLYCOSYLATION; GONADOTROPINS; HYDROXYLATION; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; TISSUE PLASMINOGEN ACTIVATOR; TYROSINE;

EID: 33749860977     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1252     Document Type: Review

References (137)

1. Bairoch, A. & Apweiler, R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res. 28, 45-46 (2000).
2. Jensen, O.N. Modification specific proteomics: characterization of post translational modifications by mass spectrometry. Curr. Opin. Chem. Biol. 8, 33-41 (2004).
3. Baumann, M. & Meri, S. Techniques for studying protein heterogeneity and posttranslational modifications. Expert Rev. Proteomics 1, 207-217 (2004).
4. Chamberlain, P. Biogenerics: Europe takes another step forward while the FDA dives for cover. Drug Discov. Today 9, 817-820 (2004).
5. Schellekens, H. Biosimiliar therapeutic agents: issues with bioequivalence and immunogenicity. Eur. J. Clin. Invest. 34, 797-799 (2004).
6. Gerngross, T. Advances in the production of protein therapeutics in yeasts and filamentous fungi. Nat. Biotechnol. 22, 1409-1414 (2004).
7. Gomord, V. & Faye, L., Posttranslational modification of therapeutic proteins in plants. Curr. Opin. Plant Biol. 7, 171-181 (2004).
8. Hu, Y-C. Baculovirus as a highly efficient expression vector in insect and mammalian cells. Acta Pharmacol. Sin. 26, 405-416 (2005).
9. Arolas, J.L., Aviles, F., Chang, J. & Ventura, S. Folding of small disulfide-rich proteins: clarifying the puzzle. Trends Biochem. Sci. 31, 292-301 (2006).
10. Wong, C.H. Protein glycosylation: new challenges and opportunities. J. Org. Chem. 70, 4219-4225 (2005).
11. Freeze, H.H. Genetic defects in the human glycome. Nat. Rev. Genet. 7, 537-551 (2006).
12. Axford, J.S., Cunnane, G., Fitzgerald, O., Bresnihan, B. & Frears, E.R. Rheumatic disease differentiation using immunoglobulin G sugar printing by high density electrophoresis. J. Rheumatol. 12, 2540-2546 (2003).
13. Holland, M. et al. Differential glycosylation of polyclonal IgG, IgG-Fc and IgGFab isolated from the sera of patients with ANCA associated systemic vasculitis. Biochim. Biophys. Acta 1760, 669-677 (2006)
14. Bill, R., Revers, L. & Wilson, I. Protein Glycosylation (Kluwer, Dordrecht, the Netherlands, 1998).
15. Willey, K. An elusive role for glycosylation in the structure and function of reproductive hormones. Hum. Reprod. Update 5, 330-355 (1999).
16. Kobata, A. Structure and function of the sugar chains of glycoproteins. Eur. J. Biochem. 209, 483-501 (1992).
17. Merkler, D.J. C-terminal amidated peptides-production by the in vitro enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity. Enzyme Microb. Technol. 16, 450-456 (1994).
18. McGrath, B. Factor IX (protease zymogen). in Directory of Therapeutic Enzymes (eds. McGrath, B. & Walsh, G.) 209-238 (CRC Press, Boca Raton, FL, 2006).
19. Gemmill, T.R. & Trimble, R.B. Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim. Biophys. Acta 1426, 227-237 (1999).
20. Jarvis, D.L., Kawar, Z.S. & Hollister, J.R. Engineering N-glycosylation pathways in the baculovirus-insect cell system. Curr. Opin. Biotechnol. 9, 528-533 (1998).
21. Gomord, V. et al. Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge. Plant Biotechnol. J. 2, 83-100 (2004).
22. Butler, M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl. Microbiol. Biotechnol. 68, 283-291 (2005).
23. Birch, J.R. & Racher, A.J. Antibody production. Adv. Drug Deliv. Rev. 58, 671-685 (2006).
24. Borth, N., Mattanovich, D., Kunert, R. & Katinger, H. Effect of increased expression of protein disulfide isomerase and heavy chain binding protein on antibody secretion in a recombinant CHO cell line. Biotechnol. Prog. 21, 106-111 (2005).
25. Harris, R.J. Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol. (Basel) 122, 117-127 (2005).
26. Smalling, R., Foot, M., Molineux, G., Swanson, S.J. & Elliott, S. Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge. Biotechnol. Annu. Rev. 10, 237-250 (2004).
27. Delorme, E. et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31, 9871-9876 (1992).
28. Egrie, J. & Browne, J. Development and characterization of a novel erythropoiesis stimulating protein (NESP). Br. J. Cancer 84 (Suppl. 1), 3-10 (2001).
29. Thorpe, R. & Swanson, S.J. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol. Dial. Transplant. 20 (Suppl. 4), 16-22 (2005).
30. Bardor, M., Faye, L. & Lerouge, P. Analysis of the N-glycosylation of recombinant glycoproteins produced in transgenic plants. Trends Plant Sci. 4, 376-380 (1999).
31. FDA Guidance Concerning Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products, April 1996. 〈http://www.fda.gov/cder/guidance/compare.htmR〉
32. Campbell, C. & Yarema, K. Large scale approaches for glycobiology. Genome Biol. 6, 236 (2005).
33. Hang, H.C. Betozzi CR. The chemistry and biology of mucin-type O-linked glycosylation. Bioorg. Med. Chem. 13, 5021-5034 (2005).
34. Brooks, S. Appropriate glycosylation of recombinant proteins for human use-implications of choice of expression system. Mol. Biotechnol. 28, 241-255 (2004).
35. Gagneux, P. & Varki, A. Evolutionary considerations in relating oligosaccharide diversity to biological function. Glycobiology 9, 747-755 (1999).
36. Shriver, Z., Raguram, S. & Sasisekhran, R. Glycomics: a pathway to a class of new and improved therapeutics. Nat. Rev. Drug Discov. 3, 863-873 (2004).
37. Grimm, C.C., Grimm, D. & Bergman, C. The analysis of oligosaccharides by mass spectrometry. ACS Symp. Ser. 849, 32-42 (2003).
38. Medzihradszky, K. Characterization of protein N-glycosylation. Methods Enzymol. 405, 116-138 (2005).
39. Browne, J. et al. Erythropoietin: gene cloning, protein structure and biological properties. Cold Spring Harb. Symp. Quant. Biol. 51, 693-702 (1986).
40. Egrie, J., Grant, J., Gillies, D., Aoki, K. & Strickland, T. The role of carbohydrate on the biological activity of erythropoietin. Glycoconj. J. 10, 263 (1993).
41. Erbayraktar, S. et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl Acad. Sci. USA 100, 6741-6746 (2003).
42. Kompella, A. & Lee, V. Pharmacokinetics of peptide and protein drugs. in Peptide and Protein Drug Delivery (ed. Lee, V.) 391-484 (Marcel Dekker, NY, 1991).
43. Takeuchi, M. & Kobata, A. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1, 337-346 (1991).
44. Wasley, L. et al. The importance of N-linked and O-linked oligosaccharides for the biosynthesis and in vivo and in vitro biological activity of erythropoietin. Blood 77, 2624-2632 (1991).
45. Nezlin, R. & Ghetie, V. Interactions of immunoglobulins outside the antigen-combining site. Adv. Immunol. 82, 155-215 (2004).
46. Jefferis, R. et al. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem. J. 268, 529-537 (1990).
47. Farooq, M., Takahashi, N., Arrol, H., Drayson, M. & Jefferis, R. Glycosylation of polyclonal and paraprotein IgG in multiple myeloma. Glycoconj. J. 14, 489-492 (1997).
48. Patel, T., Parekh, R., Moellering, B. & Prior, C. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem. J. 285, 839-845 (1992).
49. Galili, U. The α-gal epitope (Gal α1-3 Gal β1-4GlcNAc-R) in xenotransplantation. Biochimie 83, 557-563 (2001).
50. Dor, F.J., Alt, A. & Cooper, D.K. Gal α1,3 Gal expression on porcine pancreatic islets, testis, spleen, and thymus. Xenotransplantation 11, 101-106 (2004).
51. Cooper, D.K. Xenoantigens and xenoantibodies. Xenotransplantation 5, 6-17 (1998).
52. Miwa, Y. et al. Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation? Xenotransplantation 11, 247-253 (2004).
53. Jefferis, R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21, 11-16 (2005).
54. Glennie, M.J. & van de Winkel, J.G. Renaissance of cancer therapeutic antibodies. Drug Discov. Today 8, 503-510 (2003).
55. Umana, P., Jean-Mairet, J., Moudry, R., Amstutz, H. & Bailey, J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176-180 (1999).
56. Davies, J., et al. Expression of GnT III in a recombinant anti-CD 20 CHO production cell line: expression of antibodies with altered glycoforms lead to an increase in ADCC through higher affinity for Fcγ RIII. Biotechnol. Bioeng. 74, 288-294 (2001).
57. Yamane-Ohnuki, M. et al. Establishment of a FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependant cellular cytotoxicity. Biotechnol. Bioeng. 87, 614-622 (2004).
58. Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
59. Huang, L., Biolosi, S., Bales, K.R. & Kuchibhotla, U. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Anal. Biochem. 349, 197-207 (2006).
60. Pestka, S. & Langer, J. Interferons and their actions. Annu. Rev. Biochem. 56, 727-777 (1987).
61. Todd, P. & Goa, K. Interferon-γ-1b. Drugs 43, 111-122 (1992).
62. Jonasch, E. & Huluska, F. Interferons in oncological practice: a review of interferon biology, clinical applications and toxicities. Oncologist 6, 34-55 (2001).
63. Conradt, H.S. et al. Structure of the carbohydrate moiety of human interferon-β secreted by a recombinant Chinese hamster ovary cell line. J. Biol. Chem. 262, 14600-14605 (1987).
64. Runkel, L. et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm. Res. 15, 641-649 (1998).
65. Rinderknecht, E., O'Connor, B. & Rodriguez, H. Natural human interferon-γ-complete amino acid sequence and determination of sites of glycosylation. J. Biol. Chem. 259, 6790-6797 (1984).
66. Sareneva, T., Pirhonen, J., Cantell, K. & Julkunen, I. N-glycosylation of human interferon-γ-glycans at Asn-25 are critical for protease resistance. Biochem. J. 308, 9-14 (1995).
67. Sareneva, T., Pirhonen, J., Cantell, K. Kalkkinen, N. & Julkunen, I. Role of glycosylation in the synthesis, dimerization and secretion of human interferon-γ. Biochem. J. 303, 831-840 (1994).
68. Sareneva, T., Mortz, E., Tolo, H., Roepstorff, P. & Julkunen, I. Biosynthesis and N-glycosylation of human interferon-γ. Eur. J. Biochem. 242, 191-200 (1996).
69. Bennett, W.F. Two forms of tissue-type plasminogen activator (tPA) differ at a single specific glycosylation site. Thromb. Haemost. 50, 106 (1983).
70. Einarsson, M., Brandt, J. & Kaplan, L. Large scale purification of human tissue-type plasminogen activator using monoclonal antibodies. Biochim. Biophys. Acta 830, 1-10 (1985).
71. Wittwer, A. et al. Effects of N-glycosylation on in vitro activity of Bowes melanoma and human colon fibroblast derived tissue plasminogen activator. Biochemistry 28, 7662-7669 (1989).
72. Beebe, D. & Aronson, D. Turnover of tPA in rabbits: influence of carbohydrate moieties. Thromb. Res. 51, 11-22 (1988).
73. Cole, E., Nichols, E., Poisson, L., Harnois, M. & Livingston, D. In vivo clearance of tissue plasminogen activator: the complex role of sites of glycosylation and level of sialylation. Fibrinolysis 7, 15-22 (1993).
74. Andersen, D.C., Bridges, T. Gawlitzek, M. & Hoy, C. Multiple cell culture factors can effect the glycosylation of Ans-184 in CHO-produced tissue-type plasminogen activator. Biotechnol. Bioeng. 70, 25-31 (2000).
75. Pierce, J. & Parsons, T. Glycoprotein hormones: structure and function. Annu. Rev. Biochem. 50, 465-495 (1981).
76. Gharib, S., Wierman, M., Shupnik, M. & Chin, W. Molecular biology of the pituitary gonadotropins. Endocr. Rev. 11, 177-199 (1990).
77. Ulloa-Aguirre, A., Timossi, C., Damain-Matsumura, P. & Diaz, J. Role of glycosylation in function of follicle-stimulating hormone. Endocrine 11, 205-215 (1999).
78. Ulloa-Aguirre, A., Maldonado, A., Damain-Matsumura, P. & Timossi, C. Endocrine regulation of gonadotropin glycosylation. Arch. Med. Res. 32, 520-532 (2001).
79. Matzuk, M. & Boime, I. The role of the aspargine-linked oligosaccharides of the α-subunit in the secretion and assembly of human chorionic gonadotropin. J. Cell Biol. 106, 1049-1059 (1988).
80. Matzuk, M. & Boime, I. Mutagenesis and gene transfer define site-specific roles of the gonadotropin oligosaccharides. Biol. Reprod. 40, 48-53 (1989).
81. Sairam, M. Role of carbohydrates in glycoprotein hormone signal transduction. FASEB J. 3, 1915-1926 (1989).
82. Smith, P., Kaetzel, D., Nilson, J. & Baenziger, J. The sialylated oligosaccharides of recombinant bovine lutropin modulate hormone bioactivity. J. Biol. Chem. 265, 874-881 (1990).
83. Hansson, K. & Stenflo, J. Post-translational modifications in proteins involved in blood coagulation. J. Thromb. Haemost. 3, 2633-2648 (2005).
84. Kaufman, R. Post translational modifications required for coagulation factor secretion and function. Thromb. Haemost. 79, 1068-1079 (1998).
85. Itoh, S., Kawasaki, N., Ohta, M. & Hayakawa, T. Structural analysis of a glycoprotein by liquid chromatography-mass spectrometry and liquid chromatography with tandem mass spectrometry-application to recombinant human thrombomodulin. J. Chromatogr. A 978, 141-152 (2002).
86. Arruda, V.R. et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 97, 130-138 (2001).
87. Stenflo, J. & Ganrot, P. Vitamin K and the biosynthesis of prothrombin: Identification and purification of a dicumarol-induced abnormal prothrombin from bovine plasma. J. Biol. Chem. 247, 8160-8166 (1972).
88. Furie, B. & Furie, B.C. Molecular basis of vitamin K dependent γ-carboxylation. Blood 75, 1753-1762 (1990).
89. Wu, S.M., Cheung, W.F., Frazier, D. & Stafford, D.W. Cloning and expression of the cDNA for human γ-glutamyl carboxylase. Science 254, 1634-1636 (1991).
90. Knobloch, J.E. & Suttie, J.W. Vitamin K dependent carboxylase. Control of enzyme activity by the propeptide region of factor X. J. Biol. Chem. 262, 15334-15337 (1987).
91. Morris, D.P., Stevens, R.D., Wright, D.J. & Stafford, D.W. Processive post-translational modification. Vitamin K-dependent carboxylation of a peptide substrate. J. Biol. Chem. 270, 30491-30498 (1995).
92. Stenina, O., Pudota, B.N., McNally, B.A., Hommema, E.L. & Berkner, K.L. Tethered processivity of the vitamin K-dependent carboxylase: factor IX is efficiently modified in a mechanism which distinguishes Gla's from Glu's and which accounts for comprehensive carboxylation in vivo. Biochemistry 40, 10301-10309 (2001).
93. Lin, P.J., Straight, D.L. & Stafford, D.W. Binding of the factor IX γ-carboxyglutamic acid domain to the vitamin K-dependent γ-glutamyl carboxylase active site induces an allosteric effect that may ensure processive carboxylation and regulate the release of carboxylated product. J. Biol. Chem. 279, 6560-6566 (2004).
94. Camire, R.M., Larson, P.J., Stafford, D.W. & High, K.A. Enhanced γ-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry 39, 14322-14329 (2000).
95. Sun, Y.M., Jin, D.Y., Camire, R.M. & Stafford, D.W. Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X. Blood 106, 3811-3815 (2005).
96. Jia, S. et al. cDNA cloning and expression of bovine aspartyl (asparaginyl) β-hydroxylase. J. Biol. Chem. 267, 14322-14327 (1992).
97. Thim, S. et al. Amino acid sequence and post translational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 27, 7785-7793 (1988).
98. Jurlander, B. et al. Recombinant activated factor VII (rFVIIa): Characterization, manufacturing and clinical development. Semin. Thromb. Hemost. 27, 373-384 (2001).
99. Wasley, L.C., Rehemtulla, A., Bristol, J.A. & Kaufman, R.J. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J. Biol. Chem. 268, 8458-8465 (1993).
100. Yan, S.B. et al. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology 8, 655-661 (1990).
101. Gerlitz, B. et al. Effect of mutation of Asp 71 on human protein C activation and function. J. Cell. Biochem. 44 (Suppl. S14E), 201 (1990).
102. Grinnell, B.W., Yan, S.B. & Macias, W.L. Activated protein C. in: Directory of Therapeutic Enzymes (eds. McGrath, B. & Walsh, G.) 69-95 (CRC Press, Boca Raton, FL, 2006).
103. Moore, K.L. The biology and enzymology of protein tyrosine-O-sulfation. J. Biol. Chem. 278, 24243-24246 (2003).
104. Nicholas, H.B., Jr., Chan, S.S. & Rosenquist, G.L. Reevaluation of the determinants of tyrosine sulfation. Endocrine 11, 285-292 (1999).
105. Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242 (2000).
106. Farzan, M. et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96, 667-676 (1999).
107. Choe, H. et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114, 161-170 (2003).
108. Costagliola, S. et al. Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors. EMBO J. 21, 504-513 (2002).
109. Stone, S.R. & Hofsteenge, J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25, 4622-4628 (1986).
110. Higuchi, M. et al. Characterization of mutants in the factor VIII gene by direct sequencing of complementary genomic DNA. Genomics 6, 65-71 (1990).
111. Prigge, S.T., Mains, R.E., Eipper, B.A. & Amzel, L.M. New insights into copper monooxygenases and peptide amidation: structure, mechanism and function. Cell. Mol. Life Sci. 57, 1236-1259 (2000).
112. Bradbury, A.F. & Smyth, D.G. Peptide amidation. Trends Biochem. Sci. 16, 112-115 (1991).
113. Gigoux, V. et al. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid at the C terminal amide of cholecystokinin. J. Biol. Chem. 274, 20457-20464 (1999).
114. Edison, A.S., Espinoza, E. & Zachariah, C. Conformational assemblies: the role of neuropeptide structures in receptor binding. J. Neurosci. 19, 6318-6326 (1999).
115. Bignon, E. et al. SR 146131: a new potent, orally active and selective nonpeptide cholecystokinin subtype 1 receptor agonist II. In vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 289, 752-761 (1999).
116. Hong, D., Zhuang, M.Q., Li, M., Chen, C.Q. & Mao, J.F. Production of a recombinant salmon calcitonin by amidation of a precursor peptide using enzymatic transacylation and photolysis in vitro. Biochem. Biophys. Res. Commun. 267, 362-367 (2000).
117. Hong, B., Wu, B.Y. & Li, Y. Production of a C-terminal amidated recombinant salmon calcitonin in Streptomyces lividans. Appl. Biochem. Biotechnol. 110, 113-123 (2003).
118. Chakraborty, C. Nandi, S. & Sinha, S. Overexpression, purification and characterization of salmon calcitonin, a therapeutic protein, in Streptomyces avermitilis. Prot. Pept. Lett. 11, 165-173 (2004).
119. Walsh, G. Second-generation biopharmaceuticals. Eur. J. Pharm. Biopharm. 58, 185-196 (2004).
120. Furbish, F.S., Steer, C., Barranger, J., Jones, J. & Brady, R. Uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochem. Biophys. Res. Commun. 81, 1047-1053 (1978).
121. Edmunds, T. β-glucocerebrosidase, ceredase and cerezyme. in Directory of Therapeutic Enzymes (eds. McGrath, B. & Walsh, G.) 117-133 (CRC Press, Boca Raton, FL, 2006).
122. Harris, J.M., Martin, N.E. & Modi, M. Pegylation. A novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539-551 (2001).
123. Rizzari, C. et al. A pharmacological study on pegylated asparaginase used in frontline treatment of children with acute lymphoblastic leukemia. Haematologica 91, 24-31 (2006).
124. Roberts, M.J., Bentley, M.D. & Harris, J.M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459-476 (2002).
125. Veronese, F.M. & Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451-1458 (2005).
126. Foster, G.R. Pegylated interferons: chemical and clinical differences. Aliment. Pharmacol. Ther. 20, 825-830 (2004).
127. Parkinson, C. & Trainer, P.J. The place of pegvisomant in the management of acromegaly. Endocron. 13, 408-416 (2003).
128. Lyman, G.H. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin. Biol. Ther. 5, 1635-1646 (2005).
129. Goldman-Levine, J.D. & Lee, K.W. Insulin detemir-a new basal insulin analogue. Ann. Pharmacother. 39, 502-507 (2005).
130. Home, P. & Kurtzhals, P. Insulin detemir: from concept to clinical experience. Expert Opin. Pharmacother. 7, 325-343 (2006).
131. Li, H. et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24, 210-215 (2006).
132. Stomp, A.M. The duckweeds: a valuable plant for biomanufacturing. Biotechnol. Annu. Rev. 11, 69-99 (2005).
133. Wacker, M. et al. Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc. Natl Acad. Sci. USA 103, 7088-7093 (2006).
134. Walsh, G. Therapeutic insulins and their large-scale manufacture. Appl. Microbiol. Biotechnol. 67, 151-159 (2005).
135. Hopkin, M. Drug to blame for clinical-trial disaster? news@nature.com [online], April 5, 2006, http://www.nature.com/news/2006/060403/full/060403-8. html.
136. Dwek, R.A., Butters, T.D., Platt, F. & Zitzmann, N. Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov. 1, 65-75 (2002).
137. White, G.C., Beebe, A. & Nielsen, B. Recombinant Factor IX. Thromb. Haemost. 78, 261-265 (1997).